Envelope glycoprotein trimer of human immunodeficiency virus type 1 (HIV-1 Env trimer)

The envelope glycoprotein trimer of human immunodeficiency virus type 1 (HIV-1) is a complex, oligomeric structure located on the surface of the virus that is essential for viral entry into host cells. It is synthesized as a gp160 precursor, which is cleaved into two subunits, gp120 (surface subunit, responsible for receptor binding) and gp41 (transmembrane subunit, responsible for membrane fusion), forming a trimer of noncovalently associated gp120-gp41 heterodimers. The trimer binds first to CD4 on the surface of host T cells, then to a co-receptor (either CCR5 or CXCR4), and undergoes major conformational changes that allow gp41 to mediate fusion between the viral and cellular membranes. Env is the sole target for broadly neutralizing antibodies and has extensive glycosylation that both shields conserved regions and plays a role in immune evasion and antigenicity. Its high variability, structural complexity, and conformational dynamics present significant challenges for therapeutic and vaccine development but also make the trimer a central focus for antiretroviral and vaccine strategies.

Other names

HIV-1 Env trimerHIV-1 envelope glycoprotein complexgp160 trimergp120/gp41 trimerEnvelope spike

Inhibition of membrane fusion via gp41 antagonism (e.g., enfuvirtide binds gp41 and blocks conformational changes necessary for fusion) Neutralization via antibody binding to conserved epitopes (e.g., bnAbs inhibit virus by binding to gp120/gp41 and preventing entry) Blockade of CD4 binding (e.g., VRC01 mimics CD4 to block viral attachment)